The distinct catalytic site responsible for the neomorphic activity of mutant-IDH coupled with the evidence that mutant-IDH is important for AML pathogenesis, prompted rapid drug discovery to target mutant-IDH. Here, IDH1 is linked to acute myeloid leukemia.